CN111447955A - 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途 - Google Patents

99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途 Download PDF

Info

Publication number
CN111447955A
CN111447955A CN201880061342.0A CN201880061342A CN111447955A CN 111447955 A CN111447955 A CN 111447955A CN 201880061342 A CN201880061342 A CN 201880061342A CN 111447955 A CN111447955 A CN 111447955A
Authority
CN
China
Prior art keywords
composition
tumor
imaging
subject
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880061342.0A
Other languages
English (en)
Chinese (zh)
Inventor
F.O.科普
B.C.阿布鲁泽斯
D.A.拉尔夫
A.基斯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of CN111447955A publication Critical patent/CN111447955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicinal Preparation (AREA)
CN201880061342.0A 2017-07-21 2018-07-20 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途 Pending CN111447955A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535752P 2017-07-21 2017-07-21
US62/535752 2017-07-21
PCT/US2018/043176 WO2019018815A1 (en) 2017-07-21 2018-07-20 USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Publications (1)

Publication Number Publication Date
CN111447955A true CN111447955A (zh) 2020-07-24

Family

ID=65014640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880061342.0A Pending CN111447955A (zh) 2017-07-21 2018-07-20 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途

Country Status (7)

Country Link
US (1) US20190022259A1 (cg-RX-API-DMAC7.html)
EP (1) EP3655107A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020528059A (cg-RX-API-DMAC7.html)
CN (1) CN111447955A (cg-RX-API-DMAC7.html)
CA (1) CA3070494A1 (cg-RX-API-DMAC7.html)
IL (1) IL272123A (cg-RX-API-DMAC7.html)
WO (1) WO2019018815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008879A (es) * 2019-01-25 2021-08-19 Navidea Biopharmaceuticals Inc Composiciones y metodos para evaluar la patologia mediada por macrofagos.
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
WO2021067479A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11859023B2 (en) * 2020-07-08 2024-01-02 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US20160206763A1 (en) * 2015-01-21 2016-07-21 Navidea Biopharmaceuticals, Inc. Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA3039519A1 (en) * 2016-10-04 2018-04-12 Cardinal Health 414, Llc Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
IL265830B (en) * 2016-10-07 2022-07-01 Navidea Biopharmaceuticals Inc Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
CN105764529A (zh) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20160206763A1 (en) * 2015-01-21 2016-07-21 Navidea Biopharmaceuticals, Inc. Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNA M. MARCINOW 等: ""Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study"", 《JAMA OTOLARYNGOLOGY–HEAD & NECK SURGERY》 *
AVA HOSSEINI 等: ""FLUORESCENT-TILMANOCEPT FOR TUMOR MARGIN ANALYSIS IN THE MOUSE MODEL"", 《J SURG RES》 *
FREDERICK O. COPE 等: ""The inextricable axis of targeted diagnostic imaging and therapy:An immunological natural history approach"", 《NUCLEAR MEDICINE AND BIOLOGY》 *
JOHANNA SÁPI 等: ""Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy"", 《PLOS ONE》 *
ROSA FONTI 等: ""Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma"", 《J NUCL MED》 *
STANLEY P. L. LEONG 等: ""A Phase 2 Study of 99mTc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer"", 《ANN SURG ONCOL》 *

Also Published As

Publication number Publication date
EP3655107A4 (en) 2021-04-28
JP2020528059A (ja) 2020-09-17
EP3655107A1 (en) 2020-05-27
IL272123A (en) 2020-03-31
WO2019018815A1 (en) 2019-01-24
CA3070494A1 (en) 2019-01-24
US20190022259A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US20250228985A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20190022259A1 (en) Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
JP7066780B2 (ja) マクロファージおよび他のマンノース結合c型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
ES2914593T3 (es) Agentes de unión a PSMA y usos de los mismos
JP6607854B2 (ja) Cd206発現細胞関連障害を診断および処置するための組成物、方法およびキット
CA2955441C (en) Dextran conjugates for targeting macrophages and other cd296-expressing cells
JP2008531755A (ja) 二重画像化および放射線化学療法のためのコンジュゲート:組成物、製造および適応
EP2491953B1 (en) Optical imaging contrast agent, use and device thereof
JP2016528299A (ja) ビタミンb12および内因子を含む組成物およびその使用方法
US20250090697A1 (en) Zwitterionic metal chelators
US10806803B2 (en) Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20170202969A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
JP6310567B2 (ja) アテローム動脈硬化映像化用組成物、及びそれを用いたアテローム動脈硬化の診断方法
JP7252653B2 (ja) 重水素化2-アミノ-2-メチルプロピオン酸および/または2-(n-メチルアミノ)-2-メチルプロピオン酸を含有する腫瘍学的病気の磁気共鳴診断のための調剤薬、およびその調剤薬を使用した診断方法
US12440585B2 (en) Zwitterionic metal chelators
Pham Novel Dual PET And Fluorescent Bioconjugation Reagents for Biomedical Imaging
HK40062845A (zh) Psma-結合劑及其用途
KR20110031320A (ko) 치료의 모니터링

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination